Quintiles and Prodia Partner to Provide Central Lab Testing Solution in Indonesia

SINGAPORE & JAKARTA, Indonesia - Saturday, December 3rd 2011 [ME NewsWire]

-(BUSINESS WIRE)-- Quintilestoday announced an expanded partnership with Jakarta-based Prodia Clinical Laboratory, through its sister company Prodia the CRO, to facilitate rapid testing of samplesfrom patients in clinical trials in Indonesia. This will allow Quintiles’ biopharmaceutical customers to conduct clinical research in Indonesia and help establish the potential benefits of new medicines in the Indonesian population while contributing to global programs.

Under the agreement, Prodia will provide Quintiles with exclusive access to Prodia’s harmonized central laboratory for a two-year period.

“This agreement demonstrates Quintiles’ commitment to improving human health by increasing participation in global clinical research,” said Kerry Strydom, general manager of Quintiles Australia, New Zealand, Indonesia and Philippines. “Major health issues in Indonesia’s ethnically diverse population of 240 million include infectious and non-communicable diseases, with tobacco-related illnesses also on the rise.

“As new and improved medicines are developed for these conditions, it’s important that they are studied in populations for whom they are intended, including Indonesian patients.”

Gunawan Prawiro Suharto, President of Prodia the CRO, said: “As the local market leader in laboratory services, Prodia is delighted to partner with Quintiles to help establish Indonesia as a true center of excellence for delivery of clinical trials. We look forward to working with Quintiles and its global biopharma customers to develop novel therapies.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consultingand capitalsolutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

About Prodia Clinical Laboratory

Prodia Clinical Laboratory, one of the largest and the best clinical laboratories in Asia for nearly 39 years, provides a wide range of laboratory testing services. Quality is first priority from the time subjects are prepared for specimens collection up to final data analysis. Prodia was the first clinical laboratory in Indonesia to meet with ISO 9001 & ISO 15189 standards, and has recently obtained certification from the National Glycohemoglobin Standardization Program (NGSP) Level 1 for HbA1c standardization, and is in the process of accreditation by the College of American Pathologists. It has received awards as National Top Brand for three consecutive years, and owns a network of 110 branches nationwide to cover patient sampling at any needed site in the country. It has been working in the clinical trial area for nearly 15 years, and later established a sister CRO company. To learn more about Prodia Labs and Prodia the CRO, visit their websites at www.prodiathecro.comand www.prodia.co.id.

Contacts

Quintiles

Stacey Hara, Media Relations Asia Pacific, +65 6602 1583

(stacey.hara@quintiles.com)

or

Jay Johnson, Media Relations U.S., +1 919-998-2066

(jay.johnson@quintiles.com)

or

Greg Connors, Investor Relations, +1 919-998-2000

(invest@quintiles.com)